Cresset Asset Management’s Royalty Pharma RPRX Stock Holding History

Cresset Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,385	Closed	-$775K	–	2132
2024 Q3	$775K	Buy	27,385 +3,270	+14%	+$90.6K	﹤0.01%	1295
2024 Q2	$636K	Sell	24,115 -3,022	-11%	-$83.8K	﹤0.01%	1329
2024 Q1	$824K	Buy	27,137 +6,344	+31%	+$187K	﹤0.01%	1078
2023 Q4	$584K	Buy	20,793 +13,054	+169%	+$359K	﹤0.01%	1148
2023 Q3	$210K	Buy	+7,739	New	+$230K	﹤0.01%	1600

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return